Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer

NCT07528911 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT07528911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07528911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Completed
Start date
April 1, 2023
Completion date
June 22, 2025
Enrollment
687 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial high grade serous ovarian cancer